ViiV, Vertex Sue Over Mylan's Bid To Market Generic Lexiva
Law360, New York (August 24, 2012, 1:13 PM EDT) -- ViiV Healthcare Co. and Vertex Pharmaceuticals Inc. slapped Mylan Inc. with a patent infringement lawsuit in Delaware on Wednesday over Mylan's bid for U.S. regulatory approval to make and sell a generic version of the anti-HIV drug Lexiva.
North Carolina-based ViiV and Massachusetts-based Vertex said that Mylan infringed a patent owned by Vertex, and exclusively licensed to ViiV, when it submitted an abbreviated new drug application to the U.S. Food and Drug Administration seeking a green light for the manufacture, use and sale of generic fosamprenavir calcium tablets.
"If Mylan's infringement ... is not enjoined, ViiV and Vertex will suffer substantial...
Stay ahead of the curve
In the legal profession, information is the key to success. You have to know what’s happening with clients, competitors, practice areas, and industries. Law360 provides the intelligence you need to remain an expert and beat the competition.
Access to case data within articles (numbers, filings, courts, nature of suit, and more.)
Access to attached documents such as briefs, petitions, complaints, decisions, motions, etc.
Create custom alerts for specific article and case topics and so much more!